Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Icotinib is at least non-inferior to
Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one
or two chemotherapies.